MetaVia Inc. is expected to report Q3 2026 revenue of $0.00 and a consensus EPS loss of $0.94, with the current stock price of $1.17 trading significantly below the average analyst target of $19.33.
Investors are primarily focused on the upcoming 16-week topline data from the Phase 1 Part 3 titration study of lead obesity candidate DA-1726, which is anticipated in the fourth quarter of 2026.
The clinical-stage biotechnology company recently presented Phase 1 data at the Precision Liver Symposium and continues to advance its Phase 2a program for vanoglipel in MASH.
Maintaining a sufficient cash runway remains a critical priority for management, as existing liquidity is projected to support R&D operations only through the end of the 2026 fiscal year.